STOCKHOLM, Sept 10 (Reuters) – Denmark’s Novo Nordisk said on Thursday its blockbuster weight-loss drug Wegovy had been approved in China as the first GLP-1 RA class of drugs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
“The liver health-related benefits evidence extends the established evidence for Wegovy from weight management and cardiovascular health to liver health, further supporting its role in the comprehensive management of obesity and related complications,” it said in a statement.
(Reporting by Jacob Gronholt-Pedersen, writing by Anna Ringstrom, editing by Essi Lehto)
Comments